High-Dose Methotrexate-Induced Nephrotoxicity in Patients with Osteosarcoma: Incidence, Treatment, and Outcome

Cancer

Volumn 100, Issue 10, 2004, Pages 2222-2232

  Widemann, Brigitte C ^a   Balis, Frank M ^a   Kempf Bielack, Beate ^b   Bielack, Stefan ^b   Pratt, Charles B ^c   Ferrari, Stefano ^d   Bacci, Gaetano ^d   Craft, Alan W ^e   Adamson, Peter C ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^e ROYAL VICTORIA INFIRMARY   (United Kingdom)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Carboxypeptidase G2; Hemodialysis; Hemoperfusion; High dose methotrexate; Methotrexate toxicity; Renal dysfunction

Indexed keywords

CARBOXYPEPTIDASE G2; FOLINIC ACID; METHOTREXATE; RECOMBINANT ENZYME; THYMIDINE DERIVATIVE;

CLINICAL PROTOCOL; CLINICAL TRIAL; CONVALESCENCE; DIALYSIS; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; META ANALYSIS; MORTALITY; NEPHROTOXICITY; OSTEOSARCOMA; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; GAMMA-GLUTAMYL HYDROLASE; HUMANS; KIDNEY; KIDNEY FAILURE, ACUTE; METHOTREXATE; OSTEOSARCOMA; RENAL DIALYSIS;

EID: 2342634438     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20255     Document Type: Review

References (103)

1. Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol. 1987;5:2017-2031.
2. Frei E, Blum RH, Pitman SW, et al. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med. 1980;68:370-376.
3. Djerassi I. High-dose methotrexate (NSC-740) and citrovorum factor (NSC-3590) rescue: background and rationale. Cancer Chemother Rep. 1975;6:3-6.
4. Djerassi I, Kim JS, Nayak NP, Ohanissian H, Adler S. High-dose methotrexate with citrovorum factor rescue: a new approach to cancer chemotherapy. In: Tagnon HJ, Staquet MJ, editors. Advances in cancer treatment, volume 3. Monograph Series of the European Organization for Research on Treatment of Cancer. New York: Raven Press, 1977;3-6.
5. Yap HY, Blumenschein GR, Yap BS, et al. High-dose methotrexate for advanced breast cancer. Cancer Treat Rep. 1979;63:757-761.
6. Jacobs SA, Stoller RG, Chabner BA, Johns DG. 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest. 1976;57:534-538.
7. Lankelma J, van der Klein E. The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett. 1980;9:133-142.
8. Smeland E, Fuskevåg OM, Nymann K, et al. High-dose 7-hydroxymethotrexate: acute toxicity and lethality in a rat model. Cancer Chemother Pharmacol. 1996;37:415-422.
9. Bleyer W. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977;4:87-101.
10. Abelson HT, Fosburg MT, Beardsley GP, et al. Methotrexate-induced renal-impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol. 1983;1:208-216.
11. Stark AN, Jackson G, Carey PJ, Arfeen S, Proctor SJ. Severe renal toxicity due to intermediate-dose methotrexate. Cancer Chemother Pharmacol. 1989;24:243-245.
12. Pitman SW, Parker LM, Tattersall MH, Jaffe N, Frei E. Clinical trial of high-dose methotrexate (NSC-740) with citrovorum factor (NSC-3590)-toxicologic and therapeutic observations. Cancer Chemother Rep. 1975;6:43-49.
13. von Hoff DD, Penta JS, Helman LJ, Slavik M. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep. 1977;61:745-748.
14. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977;297:630-634.
15. Jürgens H, Beron G, Winkler K. Toxicity associated with combination chemotherapy for osteosarcoma: a report of the Cooperative Osteosarcoma Study (COSS 80). J Cancer Res Clin Oncol. 1983;106(Suppl):14-18.
16. Haim N, Kedar A, Robinson E. Methotrexate-related deaths in patients previously treated with cis-diamminedichloride platinum. Cancer Chemother Pharmacol. 1984;13:223-225.
17. Grem JL, King SA, Sorensen JM, Christian MC. Clinical use of thymidine as a rescue agent from methotrexate toxicity. Invest New Drugs. 1991;9:281-290.
18. Lawrenz-Wolf B, Wolfrom C, Frickel C, Fengler R, Wehinger H, Henze G. Schwere renale Methotrexat-Ausscheidungsstörung nach Hochdosis-Therapie. Klin Padiatr. 1994;206: 319-326.
19. Takami M, Kuniyoshi Y, Oomukai T, Ishida T, Yamano Y. Severe complications after high-dose methotrexate treatment. Acta Oncol. 1995;34:611-612.
20. Flobaum CD, Meyers PA. High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol. 1999;17:1589-1594.
21. Hande KR, Balow JE, Drake JC, Rosenberg SA, Chabner BA. Methotrexate and hemodialysis [letter]. Ann Intern Med. 1977;87:495-496.
22. Ahmad S, Shen FH, Bleyer WA. Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis. Arch Intern Med. 1978;138:1146-1147.
23. Bouffet E, Frappaz D, Laville M, et al. Charcoal haemoperfusion and methotrexate toxicity [letter]. Lancet. 1986;1:1497.
24. Relling MV, Stapleton FB, Ochs J, et al. Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. Cancer. 1988;62:884-888.
25. Grimes DJ, Bowles MR, Buttsworth JA, et al. Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma. Drug Saf. 1990;5:447-454.
26. Kawabata K, Makino H, Nagake Y, et al. A case of methotrexate-induced acute renal failure successfully treated with plasma perfusion and sequential hemodialysis. Nephron. 1995;71:233-234.
27. Mohty M, Peyriere H, Guinet C, Hillaire-Buys D, Blayac J, Rossi J. Carboxypeptidase G2 rescue in delayed methotrexate elimination in renal failure. Leuk Lymphoma. 2000;37:441-443.
28. Wall SM, Johansen MJ, Molony DA, DuBose TD Jr., Jaffe N, Madden T. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis. 1996;28:846-854.
29. Wakita A, Komatsu H, Banno S, et al. Delayed clearance of methotrexate in a patient with malignant lymphoma who developed renal failure. Jpn J Cancer Chemother. 1995;22:285-288.
30. 2 from Pseudomonas sp. strain RS-16. Eur J Biochem. 1985;148:447-453.
31. 2 gene and its expression in Escherichia coli and Pseudomonas putida. J Bacteriol. 1983;156:1222-1227.
32. Widemann B, Balis F, Adamson P. Dihydrofolate reductase enzyme inhibition assay for plasma methotrexate determination using a 96-well microplate reader. Clin Chem. 1999;45:223-228.
33. 10-methylpteroic acid. J Pharmacol Exp Ther. 2000; 294:894-901.
34. Widemann BC, Hetherington ML, Murphy RF, Balis FM, Adamson PC. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer. 1995;76:521-526.
35. Widemann B, Balis F, Murphy R, et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol. 1997;15:2125-2134.
36. Zoubek A, Zaunschirm HA, Lion T, Fischmeister G, Vollnhofer G, Gadner H. Successful carboxypeptidase G2 rescue in delayed methotrexate elimination due to renal failure. Pediatr Hematol Oncol. 1995;12:471-477.
37. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin OncoL 1984;2:617-624.
38. Purfürst C, Beron G, Torggler S, Kotz R, Salzer-Kuntschik M, Winkler K. Results of the COSS-77 and COSS-80 studies on adjuvant chemotherapy in osteosarcoma of the extremities. Klin Padiatr. 1985;197:233-238.
39. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6:329-337.
40. Bieling P, Bielack S, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma. Preliminary results of the cooperative COSS-86 osteosarcoma study. Klin Padiatr. 1991;203:220-230.
41. Winkler K, Bielack S, Delling G, et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer. 1990;66:1703-1710.
42. Bielack SS, Wulff B, Delling G, et al. Osteosarcoma of the trunk treated by multimodal therapy: experience of the Cooperative Osteosarcoma Study Group (COSS). Med Pediatr Oncol. 1995;24:6-12.
43. Winkler K, Torggler S, Beron G, et al. [Results of treatment in primary disseminated osteosarcoma. Analysis of the follow-up of patients in the Cooperative Osteosarcoma studies COSS-80 and COSS-82]. Onkologie. 1989;12:92-96.
44. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9:893-899.
45. Bramwell VH, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992;10:1579-1591.
46. Craft AW, Burgers JM. The European Osteosarcoma Intergroup (E.O.I.) studies 1980-1991. Cancer Treat Res. 1993;62:279-286.
47. Burgers JM. Experience of the EORTC Radiotherapy/Chemotherapy Group in osteosarcoma trials. Cancer Treat Res. 1993;62:173-175.
48. Souhami RL, Craft AW, van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup [see comments]. Lancet. 1997;350:911-917.
49. Lewis I, Weeden S, Machin D, Stark D, Craft A. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. J Clin Oncol. 2000;18:4028-4037.
50. Bacci G, Gherlinzoni F, Picci P, et al. Adriamycin-methotrexate high dose versus Adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study. Eur J Cancer Clin Oncol. 1986;22:1337-1345.
51. Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer. 1990;65:2539-2553.
52. Bacci G, Picci P, Avella M, et al. The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and Adriamycin used preoperatively. J Chemother. 1990;2:127-135.
53. Bacci G, Picci P, Ruggieri P, et al. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the limbs. Preliminary results in 100 patients treated preoperatively with high doses of methotrexate i.v. followed by cisplatin (i.a.) and Adriamycin. Chir Organi Mov. 1991;76:1-16.
54. Bacci G, Picci P, Pignatti G, et al. Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities. Clin Orthop. 1991;270:87-98.
55. Ruggieri P, De CR, Picci P, et al. Complications and surgical indications in 144 cases of nonmetastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Clin Orthop. 1993;295:226-238.
56. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993;72:3227-3238.
57. Bacci G, Mercuri M, Briccoli A, et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer. 1997;79:245-254.
58. Bacci G, Ruggieri P, Picci P, et al. Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. Results of a randomized study. J Chemother. 1996;8:70-81.
59. Bacci G, Picci P, Ferrari S, Sangiorgi L, Zanone A, Brach del Prever A. Primary chemotherapy and delayed surgery for non-metastatic teleangiectatic osteosarcoma of the extremities. Results in 28 patients. Eur J Cancer. 1994;30A: 620-626.
60. Picci P, Bacci G, Ruggieri P, et al. The treatment of localized osteosarcoma of the extremities: the Italian experience. Studies of the National Research Council. Ann Oncol. 1992;3(Suppl 2):S13-S17.
61. Bacci G, Ferrari S, Mercuri M, et al. Neoadjuvant chemotherapy for extremity osteosarcoma-preliminary results of the Rizzoll's 4th study. Acta Oncol. 1998;37:41-48.
62. Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol. 1998;16:658-663.
63. Ferrari S, Mercuri M, Picci P, et al. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori. 1999;85:458-464.
64. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/Osteosarcom-2 protocol: an updated report. J Clin OncoL 2000;18:4016-4027.
65. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, Adriamycin, and high dose of methotrexate and ifosfamide. Oncol Rep. 2000;7:339-346.
66. Chan H, Evans WE, Pratt CB. Recovery from toxicity associated with high-dose methotrexate: prognostic factors. Cancer Treat Rep. 1977;61:797-804.
67. Pratt CB, Champion JE, Fleming ID, et al. Adjuvant chemotherapy for osteosarcoma of the extremity. Long-term results of two consecutive prospective protocol studies. Cancer. 1990;65:439-445.
68. Pratt CB, Meyer WH, Rao BN, Parham DM, Fleming ID. Osteosarcoma studies at St. Jude Children's Research Hospital from 1968 through 1990. Cancer Treat Res. 1993;62:323-326.
69. Djerassi I, Ciesielka W, Kim JS. Removal of methotrexate by filtration-adsorption using charcoal filters or by hemodialysis. Cancer Treat Rep. 1977;61:751-752.
70. Saland JM, Leavey PJ, Bash RO, Hansch E, Arbus GS, Quigley R. Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol. 2002;17:825-829.
71. Gibson TP, Reich SD, Krumlovsky FA, Ivanovich P, Gonczy C. Hemoperfusion for methotrexate removal. Clin Pharmacol Ther. 1977;23:351-355.
72. Greil J, Wyss PA, Ludwig K, et al. Continuous plasma resin perfusion for detoxification of methotrexate. Eur J Pediatr. 1997;156:533-536.
73. Jambou P, Levraut J, Favier C, Ichai C, Milano G, Grimaud D. Removal of methotrexate by continuous venovenous hemodiafiltration. Contrib Nephrol. 1995;116:48-52.
74. Frappaz D, Bouffet E, Biron P, et al. [Methotrexate poisoning: value of exchange transfusion]. Pediatrie. 1987;42:257-260.
75. 10-methylpteroic acid after high-dose methotrexate. Clin Pharm Ther. 1979;26:63-72.
76. Delepine N, Delepine G, Desbois JC. A monocentric therapy study: an approach to optimize the results of the treatment of osteosarcoma by protocols based upon HDMTX, associated with systematic conservative surgery. Cancer Treat Res. 1993;62:327-332.
77. Delepine N, Delepine G, Cornille H, Brion F, Arnaud P, Desbois JC. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res. 1995;15:489-494.
78. Saeter G, Alvegard TA, Elomoa I, Stenwig AE, Holmström T, Solheim P. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol. 1991;9:1766-1775.
79. Solheim OP, Saeter G, Elomaa I, Alvegard TA. The treatment of osteosarcoma: present trends. The Scandinavian Sarcoma Group experience. Ann Oncol. 1992;3:S7-S11.
80. Saeter G, Bruland OS, Folleras G, Boysen M, Hoie J. Extremity and non-extremity high-grade osteosarcoma-the Norwegian Radium Hospital experience during the modern chemotherapy era. Acta Oncol. 1996;8:129-134.
81. Bacci G, Avella M, Picci P, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities: the Rizzoli Istitute experience. Chir Organi Mov. 1990;LXXV:57-59.
82. Bacci G, Ferrari S, Donati D, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life. Oncol Rep. 1998;5:1259-1263.
83. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl JMed. 1986;314:1600-1606.
84. Hudson M, Jaffe MR, Ayala A, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990;8:1988-1997.
85. Jaffe N, Keifer R, Robertson R, Cangir A, Wang A. Renal toxicity with cumulative doses of cis-diamminedichloro-platinum-II in pediatric patients with osteosarcoma. Effect on creatinine clearance and methotrexate excretion. Cancer. 1987;59:1577-1581.
86. Miser J, Arndt C, Smithson W, et al. Treatment of high-grade osteosarcoma (OGS) with ifosfamide (Ifos), mesna (Mes), Adriamycin (Adr), high-dose methotrexate (Hdmtx), with or without cisplatin (CDDP) [meeting abstract 1262]. Proc Am Soc Clin Oncol. 1992;11:366.
87. Miser J. Arndt C, Smithson W, et al. Treatment of high-grade osteosarcoma (OGS) with ifosfamide (IFOS), mesna (MES), Adriamycin (ADR), high-dose methotrexate (HD-MTX) with or without cisplatin (CDDP). Results of two pilot trials [meeting abstract 1442]. Proc Am Soc Clin Oncol. 1994;13:421.
88. Patel SJ, Lynch JW Jr., Johnson T, et al. Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults. Am J Clin Oncol. 2002;25:489-495.
89. Howell SB, Blair HE, Uren J, Frei E. Hemodialysis and enzymatic cleavage of methotrexate in man. Eur J Cancer. 1978;14:787-792.
90. Collett P, Raghavan O, Salasoo S, Tattersall M, Tiller D. Successful treatment of methotrexate-induced renal failure by haemodialysis. Aust N Z J Med. 1977;7:441.
91. Langleben A, Hollomby D, Hand R. Case report: management of methotrexate toxicity in an anephric patient. Clin Invest Med. 1982;2:129-132.
92. Frappaz D, Bouffet E, Cochat P, et al. Hemoperfusion on charcoal and hemodialysis in acute poisoning caused by methotrexate. Presse Med. 1988;17:1209-1213.
93. Thierry FX, Dueymes JM, Vernier I, Conte JJ. Role of hemodialysis and plasma exchange in the removal of methotrexate [letter]. Presse Med. 1988;17:2356.
94. Gauthier E, Gimonet JF, Piedbois P, et al. Efficacité de l'hémodialyse dans un cas d'intoxication aiguë par le methotrexate. Presse Med. 1990;19:2023-2025.
95. Thomson AH, Daly M, Knepil J. Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma. Cancer Chemother Pharmacol. 1996;38:566-570.
96. Montagne N, Milano G, Caldani C, et al. Removal of methotrexate by hemodiafiltration. Cancer Chemother Pharmacol. 1989;24:400-401.
97. Kepka L, De Lassence A, Ribrag V, et al. Successful rescue in a patient with high dose methotrexate-induced nephrotoxicity and acute renal failure. Leuk Lymphoma. 1998;29(1-2):205-209.
98. McIvor A. Charcoal hemoperfusion and methotrexate toxicity. Nephron. 1991;58:378.
99. Benezet S, Chatelut E, Bagheri H, et al. [Inefficacy of exchange-transfusion in case of a methotrexate poisoning]. Bull Cancer. 1997;84:788-790.
100. Shinozaki T, Watanabe H, Tomidokoro R, Yamamoto K, Horiuchi R, Takagishi K. Successful rescue by oral cholestyramine of a patient with methotrexate nephrotoxicity: nonrenal excretion of serum methotrexate. Med Pediatr Oncol. 2000;34:226-228.
101. Molina R, Fabian C, Cowley B. Use of charcoal hemoperfusion with sequential hemodialysis to reduce serum methotrexate levels in a patient with acute renal insufficiency. Am J Med. 1987;82:350-352.
102. Thierry FX, Vernier I, Dueymes JM, et al. Acute renal failure after high-dose methotrexate therapy. Role of hemodialysis and plasma exchange in methotrexate removal [letter]. Nephron. 1989;51:416-417.
103. van den Bongard H, Mathot R, Boogerd W, et al. Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure. Cancer Chemother Pharmacol. 2001;47:537-540.